Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05362253
Other study ID # [2021]NO.(024)
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date December 10, 2021

Study information

Verified date May 2022
Source Second Affiliated Hospital of Nanchang University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To observe the effect of micro-conjunctival autografting combined with amniotic membrane transplantation on the postoperative recurrence, complications and ocular surface symptoms among patients with recurrent pterygium.


Description:

Recurrent pterygium is a common postoperative complication of pterygium surgery, the postoperative recurrence rate is about 1.44% and needs careful treatment. At present, surgical is the main and most effective treatment of recurrent pterygium. Among various surgical methods, autologous conjunctival transplantation is regarded as the first choice in normal conditions. However, the scope of conjunctival transplantation is positively correlated with the degree of ocular surface damage. Therefore, our research aimed to use micro conjunctival transplantation(1.5mm×3.0mm) to reconstruct limbal conjunctiva and amniotic membrane to cover the whole pterygium resection area to better protect conjunctival sac and ocular surface.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 10, 2021
Est. primary completion date May 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. age?18; 2. relapsed after pterygium surgery once; 3. invading the cornea 2.00~5.00mm. Exclusion Criteria: 1. having obvious severe systemic organic diseases and mental diseases; 2. In lactation or pregnancy or planned pregnancy; 3. combined with eye diseases such as severe eyelid insufficiency, dry eye, chemical injury of cornea and conjunctiva, etc.; 4. used drugs that may affect the growth and metabolism of corneal epithelium within four weeks before inclusion in the study; 5. received pterygium surgery twice or more.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation
Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm ~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing.
Conventional Autologous Conjunctival Transplantation
Routine disinfection and anaesthesia. To bluntly separate and excise pterygium. Remove pterygium tissue on the corneal surface with a round blade. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation.

Locations

Country Name City State
China the Second Affiliated Hospital of Nanchang University Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Yifeng Yu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes of pterygium size The pterygium size is recorded by the longest length of its invasion into the cornea. Day 0#3#7 and14, Month 1#3 and 6.
Other Changes of intraocular pressure To monitor intraocular pressure during the period of useing glucocorticoids. Day 0#3#7 and14, Month 1#3 and 6.
Primary Changes of grade of conjunctival hyperplasia Grade 1, no significant difference from normal eyes (no recurrence); Grade 2, a little episcleral vessels in the pterygium excision area, which extends to the corneoscleral limbus but does not exceed, and there is no fibrous tissue hyperplasia (no recurrence); Grade 3, having proliferative fibrous tissue in the resection area, which does not exceed the limbus (no recurrence); Grade 4, the cornea is invaded by proliferative fibrous tissue, and this grade is true pterygium recurrence (recurrence). Day 0#3#7 and14, Month 1#3 and 6.
Primary Changes of Schirmer test I 5-minute Schirmer test I Day 0#3#7 and14, Month 1#3 and 6.
Primary Changes of ocular surface symptom scores Include dryness, burning, foreign body and pain sensation. The full score of each symptom is 100 points, with a score of 0 reflecting no discomfort, 100 was considered as the maximum discomfort. Day 0#3#7 and14, Month 1#3 and 6.
Secondary Changes of corneal epithelial repair time Corneal fluorescein sodium staining was applied to assess the epithelial repair after operation. Day 0#3#7 and14, Month 1#3 and 6.
Secondary Changes of visual acuity To observe the changes of visual acuity around operation. Day 0#3#7 and14, Month 1#3 and 6.
See also
  Status Clinical Trial Phase
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Completed NCT02007174 - Bevacizumab Injection for Recurrent Pterygium N/A
Active, not recruiting NCT02530801 - Strategies for Management of Recurrent Pterygium Phase 4
Recruiting NCT04463901 - Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C N/A
Completed NCT01744756 - Subconjunctival Bevacizumab and Recurrent Pterygium Phase 2/Phase 3
Completed NCT02059837 - Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery N/A
Completed NCT01319721 - Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane N/A